PREPRINT (not peer reviewed)

Estimating Cardiac 5-HT2B Safety Margins for Repeated Low-Dose Psilocybin Using an Exposure-Response Model

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: bioRxiv
Date: 2026-07-22
Source: bioRxiv
DOI: 10.64898/2026.07.19.739440
PubMed: Unavailable

Authors

Tyler W. J.; Sellers E.; McDonnell M. B.

Watch author

Derived topics and classifications

psilocybin psilocin Anxiety Pharmacology Mechanism of Action Receptor Pharmacology Microdosing Observational Study Safety Toxicity Observational Study

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Chronic pain education: past, present, and future of psychedelics for the management of chronic painPain Medicine · 2024-12-09 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-04 Effects of a Psychedelic, Tropical Tea, Ayahuasca, on the Electroencephalographic (EEG) Activity of the Human Brain during a Shamanistic RitualUnknown journal · 2000-12-31 Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ ConcernsThe Journal of Law Medicine & Ethics · 2024-12-31 Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based surveyPalliative Medicine · 2024-01-21 A Working Paper: Memo on the Religious Implications of the Consciousness-Changing Drugs (LSD, Mescalin, Psilocybin)Journal for the Scientific Study of Religion · 1963-12-31 Therapeutic advances in fibromyalgia: one year in review 2026.Unknown journal · 2026-06-16 5 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions.Unknown journal · 2026-03-04